PT Medela Potentia Tbk Declares FY2025 Dividend and Appoints New President Director to Sustain Long-Term Growth

PT Medela Potentia Tbk (IDX: MDLA) held its Annual General Meeting of Shareholders (AGMS) on Tuesday, approving key resolutions covering dividend distribution, changes to the Board of Directors, and the Company’s strategic growth priorities for 2026.

Shareholders approved a cash dividend distribution of Rp176.56 billion, equivalent to Rp12.6 per share, reflecting the Company’s solid financial performance and continued commitment to delivering sustainable value to shareholders.

Corporate Secretary Mr. Wimala Widjaja stated that the dividend payout demonstrates the Company’s consistency in maintaining shareholder returns since becoming a publicly listed company. For FY2025, MDLA increased its dividend payout ratio to 45% of net profit, compared with 40% in the previous year.

“The Company maintained its regular dividend distribution of 40% of net profit, while adding an extra 5% dividend payout. Total dividend distribution reached Rp12.6 per share, representing a 28.5% increase compared with the previous year,” said Mr. Wimala.

During the AGMS, shareholders also approved the resignation of Mr. Krestijanto Pandji as President Director. The Company expressed appreciation for his contribution in strengthening corporate governance, accelerating business transformation, and enhancing the Company’s operational resilience and performance.

The AGMS subsequently appointed Mrs. Juliwaty as the new President Director of the Company. Prior to her appointment, Juliwaty served as President Director of PT Anugrah Argon Medica (AAM), a subsidiary of MDLA, and brings extensive experience in Indonesia’s healthcare industry.

The leadership transition forms part of the Company’s long-term strategy to maintain business continuity and reinforce sustainable growth momentum.

“This leadership transition is expected to further strengthen the organization’s foundation and support the continued acceleration of the Company’s business strategy,” Mr. Wimala added.

Strengthening Distribution Infrastructure and Strategic Partnerships

As part of its long-term growth strategy, MDLA continues to strengthen its national distribution infrastructure, including the planned inauguration of a new office and warehouse facility for AAM’s Medan branch. The expansion is expected to enhance pharmaceutical distribution coverage across western Indonesia.

The Company also added three new principals during the first quarter of 2026 as part of its portfolio strengthening strategy and efforts to enhance its competitive positioning. Moving forward, MDLA will continue to selectively explore additional principal partnerships to expand product offerings, strengthen strategic collaborations, and support sustainable business growth.

In the medical devices segment, the Company is currently exploring potential collaborations with global medical device companies as part of its broader business diversification strategy and portfolio value enhancement initiatives.

Investor Relations Director Mr. Harris Lesmana stated that these initiatives are aligned with the Company’s long-term growth roadmap.

“The Company continues to strengthen its growth foundation through distribution infrastructure expansion, additional principal partnerships, and strategic collaboration opportunities in the medical devices business with global partners to bring high-quality locally manufactured healthcare products to the market,” said Mr. Harris.

Solid First Quarter Performance Amid Challenging Economic Conditions

MDLA recorded solid financial performance during the first quarter of 2026 despite ongoing economic challenges. Net sales increased to Rp4.03 trillion as of March 31, 2026, compared with Rp3.9 trillion in the same period last year.

Revenue grew 3.4% year-on-year, while profit for the period rose 7.4% to Rp119.32 billion. The improvement was supported by strong pharmaceutical sales performance and operational efficiencies across the Company’s distribution network.

Pharmaceutical products remained the largest contributor, generating Rp3.26 trillion in sales, up from Rp2.7 trillion in the first quarter of 2025. Meanwhile, medical devices contributed Rp394.5 billion, while healthcare products contributed Rp380.2 billion.

Advancing ESG Commitments Across Operations

MDLA also continues to strengthen the implementation of Environmental, Social, and Governance (ESG) principles across its operations.

On the environmental front, the Company has started utilizing electric vehicles for pharmaceutical distribution activities, following the earlier deployment of 106 electric motorcycles across 15 branches in 13 cities.

From a social perspective, the Company will continue its free health check-up programs in multiple cities across Indonesia as part of its contribution to chronic disease prevention and public health awareness initiatives.

On governance, MDLA remains committed to implementing Good Corporate Governance (GCG) principles consistently across all operational lines and subsidiaries.

Cash Dividend Schedule

• Cum Dividend (Regular and Negotiated Market): May 22, 2026

• Ex Dividend (Regular and Negotiated Market): May 25, 2026

• Cum Dividend (Cash Market): May 26, 2026

• Ex Dividend (Cash Market): May 29, 2026

• Recording Date: May 26, 2026

• Cash Dividend Payment Date: June 17, 2026

  
  

Board of Directors and Board of Commissioners

Board of Directors

• President Director: Juliwaty

• Director: Wimala Widjaja

• Director: Edbert Orotodan

Board of Commissioners

• President Commissioner: Stanley Ch. Budihardja

• Independent Commissioner: Lukas Setia Atmaja, M.Sc.